Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

82.38 +1.88 (+2.33%)
Streaming Delayed Price Updated: 3:02 PM EDT, Jun 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Arrowhead Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction ↗
Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined upcoming clinical catalysts, early commercial trends and pipeline priorities during a Jefferies fireside chat, with Chief Medical Officer... 
Via MarketBeat
News headline image
Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum ↗
Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives said the company is entering a key period marked by new regulatory approvals, early commercial progress for REDEMPLO and upcoming Phase 3 data in... 
Via MarketBeat
News headline image
Arrowhead Pharmaceuticals Eyes $4B REDEMPLO Opportunity as RNAi Pipeline Readouts Near ↗
Arrowhead Pharmaceuticals (NASDAQ:ARWR) is moving into a more commercial phase while continuing to expand its RNA interference pipeline, Chief Executive Officer Chris Anzalone said during a... 
Via MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Soars 70% After Hours on REDEMPLO Launch Momentum and Strong Q2 Earnings Beat ↗
Via Chartmill
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Presents a High-Growth, Technical Breakout Opportunity ↗
Via Chartmill
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reports Profitable Quarter on Strong Drug Launch ↗
Via Chartmill
Arrowhead Pharmaceuticals Stock Jumps 22% After Morgan Stanley Hikes Price Target ↗
Via Stocktwits
News headline image
Arrowhead (ARWR) Q2 2026 Earnings Transcript ↗
Arrowhead (ARWR) Q2 2026 Earnings Transcript 
Via The Motley Fool
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Emerges as a Growth Stock with a Constructive Technical Setup ↗
Arrowhead Pharmaceuticals (ARWR) combines strong revenue growth and profitability with a bullish technical chart pattern, signaling a potential breakout for this RNAi therapy developer. 
Via Chartmill
News headline image
Sarepta's RNA Renaissance: 35% Surge as siRNA Breakthrough Silences Skeptics
CAMBRIDGE, MA — March 26, 2026 — Shares of Sarepta Therapeutics (NASDAQ: SRPT) skyrocketed 35% in early trading today, reaching levels not seen since the company’s early days in Duchenne Muscular... 
Via MarketMinute
News headline image
Sarepta Therapeutics (SRPT) Stock Surges 34.98% on Breakthrough Clinical Data
CAMBRIDGE, MA — March 26, 2026 — Shares of Sarepta Therapeutics (NASDAQ:SRPT) skyrocketed 34.98% in heavy trading today, marking the biotech giant's most explosive single-day gain in over two years.... 
Via MarketMinute
News headline image
The Great Rotation: How the 'One Big Beautiful Bill Act' is Igniting a Small-Cap Renaissance
The U.S. financial landscape is undergoing a tectonic shift as the "One Big Beautiful Bill Act" (OBBBA), signed into law on July 4, 2025, begins to exert its full influence on the equity markets. For... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
Arrowhead (ARWR) Q1 2026 Earnings Call Transcript ↗
Arrowhead (ARWR) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Ciena’s AI-Driven Return: Networking Giant to Join S&P 500 Benchmark
In a move signaling the stock market’s continued embrace of the artificial intelligence infrastructure trade, S&P Dow Jones Indices announced late Wednesday that Ciena Corporation (NYSE: CIEN) will... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Arrowhead Stock Has Skyrocketed 290% in One Year, and One Fund Trimmed Its Holdings by $4 Million ↗
This biotech firm develops RNAi therapeutics for rare and serious diseases, leveraging clinical partnerships to advance its pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
Is Arrowhead Pharmaceuticals Stock a Buy or Sell After the CEO Sold Shares Worth $5.4 Million? ↗
Arrowhead Pharmaceuticals, a leader in RNAi therapeutics, reported a significant insider sale amid a year of exceptional stock gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Nvidia’s $5 Trillion Peak Sparks Massive Nasdaq Retreat as Investors Pivot to Value
The tech-heavy Nasdaq Composite faced a stark reversal on January 8, 2026, as a wave of profit-taking in high-flying artificial intelligence stocks, led by Nvidia (NASDAQ: NVDA), dragged the index... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
The Great Rotation: Small-Caps Lead 2026 Market Charge as Tech Giants Stumble
The first week of 2026 has delivered a definitive verdict on the next phase of the bull market: the era of mega-cap dominance is yielding to the rise of the small-cap. In a dramatic "Great Rotation,"... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Why Did ARWR Stock Surge Over 15% Pre-Market Today? ↗
The preliminary results from Phase 1/2a clinical trials of the company’s RNA interference (RNAi) therapies suggest the treatments may reduce body fat and improve metabolic health in patients,... 
Via Stocktwits
News headline image
The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts... 
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
Why Arrowhead Pharmaceuticals Stock Surged by Over 23% Today ↗
These are historic days for the company, following its first FDA approval. 
Via The Motley Fool
News headline image
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Reports Strong Q4 2025 Revenue Beat and First FDA Approval ↗
Arrowhead Pharmaceuticals exceeded Q4 2025 revenue expectations, driven by its first FDA-approved drug and strong collaborations, marking its shift to a commercial-stage company. 
Via Chartmill
News headline image
Arrowhead (ARWR) Q4 2025 Earnings Call Transcript ↗
Arrowhead (ARWR) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
FDA Clears Arrowhead Pharma's First-Ever Home Injection For Rare Fat Disorder ↗
Arrowhead Pharmaceuticals won FDA approval for Redemplo (plozasiran), an siRNA drug reducing high triglycerides in adults with rare FCS. 
Via Benzinga
News headline image
CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial ↗
CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its gene editing platform. 
Via Benzinga
News headline image
Privium Fund Management Sells Into Strength in Pharma Stock ↗
Privium Fund Management Sells Into Strength in Pharma Stock 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals ↗
Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action. 
Via Benzinga
News headline image
Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal ↗
The announcement of a landmark deal with a pharmaceutical giant validates Arrowhead's technology. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.